ArticleRespiratory research2025
DNMT1 deficiency promotes pulmonary vascular remodeling in pulmonary hypertension through epigenetic upregulation of BMP7.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPulmonary hypertension (PH) is a progressive cardiopulmonary disorder marked by pathological vascular remodeling, predominantly driven by the hyperproliferation of pulmonary artery smooth muscle cells (PASMCs). Although bone morphogenetic protein 7 (BMP7) has been implicated in PASMCs dysregulation, the precise upstream mechanisms governing its expression in PH remain elusive.
methodsIn vitro and in vivo models of hypoxia-induced PH were employed. The mRNA and protein levels of the different molecules were quantified using qRT-PCR and Western blot. The role of BMP7 in PASMCs proliferation, cell cycle progression and apoptosis were assessed using Cell Counting Kit-8 (CCK-8) assays, Western blotting, immunofluorescence, and flow cytometry. Moreover, the epigenetic regulatory mechanisms of BMP7 were elucidated using Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) and quantitative methylation-specific PCR (qMSP). In vivo functional roles of BMP7 were validated using recombinant protein administration and AAV5-mediated gene knockdown in hypoxic mice, with evaluations of hemodynamics, echocardiography, and vascular remodeling.
resultsHypoxia significantly upregulated BMP7 expression in PASMCs and lung tissues of PH models. Exogenous BMP7 enhanced PASMCs proliferation, accelerated cell cycle progression and suppressed apoptosis. Conversely, BMP7 knockdown attenuated these pro-proliferative and anti-apoptotic responses. Mechanistically, DNMT1 was downregulated under hypoxia, and its genetic or pharmacological inhibition elevated BMP7 expression, whereas DNMT1 overexpression suppressed BMP7. ChIP-qPCR verified DNMT1 binding to the BMP7 promoter CpG island, and qMSP confirmed that DNMT1 loss reduced BMP7 promoter methylation. Consistent with a pathogenic role, BMP7 knockdown alleviated hypoxia-induced right ventricular hypertrophy and vascular remodeling, while BMP7 supplementation exacerbated these phenotypes.
conclusionsOur study unveils the DNMT1-BMP7 axis as a critical epigenetic pathway in PH. Hypoxia-induced DNMT1 downregulation derepresses BMP7 via promoter hypomethylation, driving PASMCs proliferation and pathological vascular remodeling. Targeting this axis may offer novel therapeutic strategies for PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.